Formulation Development
MilliporeSigma Acquires BSSN Software to Accelerate Customers’ Digital Transformation in the Lab
MilliporeSigma has acquired BSSN Software, a Darmstadt, Germany-based laboratory informatics company that makes data more readily accessible for ease of integration, collaboration, analysis and…..
Huge Untapped Potential for Rheumatoid Arthritis Treatment by Targeting OX40
A new study led by experts from the University of Tsukuba first published in Annals of the Rheumatic Diseases in July found that OX40-expressing follicular helper T cells contributed to inflammation by regulating……
Spring Bank Announces Collaborative Research Agreement with University of Texas Southwestern Medical School
Spring Bank Pharmaceuticals, Inc. recently announced that it has entered into a research agreement with the University of Texas Southwestern Medical School to evaluate….
Colorcon & TruTag Technologies Enter Development Agreement
Colorcon and TruTag Technologies, Inc. recently announced execution of a development agreement to enable on-dose verification technology for tablets by combining TruTag’s….
Cambrex to be Acquired by the Permira Funds
Cambrex Corporation recently announced it has signed a definitive agreement to be acquired by an affiliate of the Permira funds in a transaction valued at approximately……
Cambrex to Double Size of Edinburgh Solid Form Screening Facility
Cambrex Corporation, the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that it is…
Principia Announces Update to Ongoing Phase 2 Clinical Trial
Principia Biopharma Inc. recently announced updates to its immune thrombocytopenia (ITP) program for PRN1008. The ongoing open-label, dose-finding clinical trial investigating PRN1008 in patients with…
Foamix Announces $64-Million Capital Financing Investment by Perceptive Advisors & OrbiMed
Foamix Pharmaceuticals Ltd. recently announced it has secured up to $64 million in financing from Perceptive Advisors and OrbiMed. The financing consists of term loans…
Atlas Nanotech Opens First Revenue Stream With Gem Labs Contract
The contract calls for Atlas to sell stabilized and functionalized silver nanoparticles to Gem Labs for use in the manufacture of one of Gem Labs proprietary products.
LabTwin Partners With Bonneville Labs & Lab Launch to Give Biotech Startups Access to World’s First Voice & AI-Powered Digital Lab Assistant
LabTwin GmbH, the world’s first voice and AI-powered digital lab assistant, recently announced partnerships with CA-based life science shared lab facilities Bonneville Labs and Lab Launch to……
Quotient Sciences to Recapitalize With Global Private Equity Firm
Quotient Sciences and global investment firm Permira recently announced that a company backed by the Permira Funds has signed a definitive agreement to acquire a majority stake in…….
Pfenex & Arcellx Announce Development, Evaluation & License Agreement
Pfenex Inc. and Arcellx, Inc. recently announced a Development, Evaluation, and License agreement under which Arcellx gains access to the proprietary Pfenex Expression Technology platform to advance……
Noramco & SPI Pharma Announce Availability of New Excipient Compatibility Study
Noramco and SPI Pharma recently announced they have completed work on an excipient compatibility study examining a range of options for the development of….
Catalent Extends Global Commercial Spray Drying Capabilities
Catalent, Inc. recently announced it has significantly expanded the capacity of its global spray drying operations through an agreement with….
Incyte & Zai Lab Announce Collaboration & License Agreement
Incyte and Zai Lab Ltd. recently announced that the companies have entered into a collaboration and license agreement for the development and commercialization of
Amicus Therapeutics & Catalent Biologics Enter Strategic Partnership
Amicus Therapeutics, Inc. has entered into a strategic manufacturing agreement with Paragon Gene Therapy, a unit of Catalent Biologics, for clinical manufacturing capabilities and capacity for….
Calithera Biosciences Initiates Phase 1/2 Trial
Calithera Biosciences, Inc. recently announced treatment of the first patient in a Phase 1/2 open-label clinical trial of the glutaminase inhibitor telaglenastat (CB-839) in combination…
Appili Therapeutics Signs $3-Million Grant to Develop Antibiotics That Target Superbugs
Appili Therapeutics Inc. recently announced the United States Department of Defense, (DOD) Congressionally Directed Medical Research Programs, Peer Reviewed Medical Research Program (PRMRP) has completed…
Amicus Therapeutics & Brammer Bio Enter Strategic Development & Manufacturing Collaboration
Amicus Therapeutics, Inc. has entered into a strategic manufacturing collaboration with Thermo Fisher Scientific. Thermo Fisher, a best-in-class contract development and manufacturing organization (CDMO) with…
Therapeutic Solutions International Obtains Exclusive License for Patented Clinical Stage Adult Stem Cell
Therapeutics Solutions International, Inc. recently announced signing of a license agreement providing exclusive rights to a patented adult stem cell for development of therapeutics in…
